Autoimmune Bullous Skin Disorders with Immune Checkpoint Inhibitors Targeting PD-1 and PD-L1

Monoclonal antibodies (mAb) targeting immune checkpoint pathways such as cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and programmed death 1 (PD-1) may confer durable disease control in several malignancies. In some patients, immune checkpoint mAb cause cutaneous immune-related adverse event...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Cancer Immunol Res
Autors principals: Naidoo, Jarushka, Schindler, Katja, Querfeld, Christiane, Busam, Klaus, Cunningham, Jane, Page, David B., Postow, Michael A., Weinstein, Alyona, Lucas, Anna Skripnik, Ciccolini, Kathryn T., Quigley, Elizabeth A., Lesokhin, Alexander M., Paik, Paul K., Chaft, Jamie E., Segal, Neil H., D‘Angelo, Sandra P., Dickson, Mark, Wolchok, Jedd D., Lacouture, Mario E.
Format: Artigo
Idioma:Inglês
Publicat: 2016
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5241697/
https://ncbi.nlm.nih.gov/pubmed/26928461
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/2326-6066.CIR-15-0123
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars